BioNJ’s Health Equity in Clinical Trials Initiative Overview
Health Equity in Clinical Trials is necessary to improve the understanding of health outcomes in under-represented populations, expand access to medical advancements for these populations and bolster trust in the biopharma industry/health care system. BioNJ is committed to helping Patients Live Longer Better Lives. Health Equity in Clinical Trials is required to ensure that all Patients have access to the therapies and cures that they need. The life sciences sector plays a major role in addressing Equity of Care and BioNJ believes that role can be expanded. We have a moral imperative that requires business solutions that address this critical need.
BioNJ is committed to the vision of Health Equity for All. Therefore, we have launched BioNJ’s Health Equity in Clinical Trials Initiative which will consider concrete issues we can tackle with impact, identify long-term interventions, support companies to improve equity in their clinical trials, consider best practices and shape and impact policy.
A focus on Health Equity in Clinical Trials will help to realize:
- An improved understanding of health outcomes in under-represented populations
- Expanded access for those populations to potential treatment advances
- Bolstered confidence in the biopharmaceutical industry and health care system which would result in benefits such as helping to overcome vaccine hesitancy
- Identify and help develop the next generation of diverse clinical trial leaders and community partners
Contact BioNJ at BioNJ@BioNJ.org to learn how you can get involved.
Deliverables of BioNJ’s Health Equity in Clinical Trials Initiative:
What is Health Equity
Defining Diversity: Alignment with FDA Draft Guidance
The Impact of Clinical Trials in New Jersey
BioNJ’s Health Equity in Clinical Trials Steering Committee
Contact Us to Learn More
To discuss your interest in supporting this initiative or for additional information:
Ian McLaughlin, Ph.D.
Executive Director, Government Affairs